.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,747,020

« Back to Dashboard

Claims for Patent: 6,747,020

Title: Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor
Abstract:Methods of using eplerenone, an angiotensin converting enzyme inhibitor and optionally a diuretic are described for treatment of heart failure and hypertension.
Inventor(s): Perez; Alfonzo T. (Lake Forest, IL), Asner; Debra J. (Morton Grove, IL), LaChapelle; Richard J. (Wilmette, IL), Alexander; John C. (Princeton, NJ), Roniker; Barbara (Chicago, IL)
Assignee: Pharmacia Corporation (St. Louis, MO)
Application Number:10/077,134
Patent Claims: 1. A co-therapy method for treating a cardiovascular disorder in a subject comprising administering a first amount of an angiotensin converting enzyme inhibitor and a second amount of eplerenone to the subject, wherein the first amount and second amount together comprise a therapeutically effective amount of the inhibitor and eplerenone; and wherein the cardiovascular disorder is selected from the group consisting of heart failure and hypertension.

2. The method of claim 1 wherein the cardiovascular disorder is heart failure.

3. The method of claim 2 wherein eplerenone is administered in a daily dose range from about 1 mg to about 400 mg.

4. The method of claim 2 wherein eplerenone is administered in a daily dose range from about 2 mg to about 150 mg.

5. The method of claim 2 wherein the cardiovascular disorder is congestive heart failure.

6. The method of claim 1 wherein the cardiovascular disorder is hypertension.

7. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat and spirapril.

8. The method of claim 4 wherein the cardiovascular disorder is heart failure.

9. The method of claim 8 wherein eplerenone is administered in a daily dose range from about 1 mg to about 400 mg.

10. The method of claim 8 wherein eplerenone is administered in a daily dose range from about 2 mg to about 150 mg.

11. The method of claim 8 wherein the cardiovascular disorder is congestive heart failure.

12. The method of claim 7 wherein the cardiovascular disorder is hypertension.

13. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is benazepril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

14. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is moexipril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

15. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is perindopril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

16. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is quinapril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

17. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is ramipril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

18. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is trandolapril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

19. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is cilazapril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

20. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is fosinopril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

21. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is spirapril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

22. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is enalapril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

23. The method of claim 22 wherein the angiotensin converting enzyme inhibitor is administered in a daily dose range of about 5 mg to about 40 mg.

24. The method of claim 1 wherein the angiotensin converting enzyme inhibitor is lisinopril, or a pharmaceutically acceptable salt, ester or prodrug thereof.

25. The method of claim 24 wherein the angiotensin converting enzyme inhibitor is administered in a daily dose range of about 5 my to about 20 mg.

26. The method of claim 1 further characterized by the angiotensin converting enzyme inhibitor and eplerenone being used in the co-therapy in a weight ratio range from about 0.1-to-one to about twenty-five-to-one of the angiotensin converting enzyme inhibitor to eplerenone.

27. The method of claim 26 wherein the weight ratio range is from about 0.5-to-one to about fifteen-to-one.

28. The method of claim 26 wherein the weight ratio range is from about 0.5-to-one to about five-to-one.

29. The method of claim 1 wherein eplerenone is administered in a daily dose range from about 1 mg to about 400 mg.

30. The method of claim 1 wherein eplerenone is administered in a daily dose range (from about 2 mg to about 150 mg.

31. The method of claim 1 further characterized by administering the angiotensin converting enzyme inhibitor and eplerenone in a sequential manner.

32. The method of claim 1 further characterized by administering the angiotensin converting enzyme inhibitor and eplerenone in a substantially simultaneous manner.

33. The method of claim 1 wherein the subject as a human.

34. The method of claim 1 wherein the subject is classified in New York Heart Association class III or class IV.

35. The method of claim 1 further comprising administering a third amount of a diuretic to the subject.

36. The method of claim 35 wherein the cardiovascular disorder is heart failure.

37. The method of claim 36 wherein the cardiovascular disorder is congestive heart failure.

38. The method of claim 35 wherein the cardiovascular disorder is hypertension.

39. The method of claim 35 further comprising administering a fourth amount of digoxin to the subject.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc